PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. The company operates through three segments: Biopharma, Consumer Health, and Others. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in research an, development, production, and distribution of pharmaceutical and biological prescription medicines to treat colorectal cancer, head and neck cancer, multiple sclerosis, infertility, growth hormone disorders, and diabetes, as well as thyroid disorders, such as hypothyroidism. In addition, it is involved in the office/property leasing and management activities. The company was formerly known as PT Merck Indonesia Tbk and changed its name to PT Merck Tbk in June 2002. The company was founded in 1970 and is headquartered in Jakarta Timur, Indonesia. PT Merck Tbk operates as a subsidiary of Merck Holding GmbH.
Metrics to compare | MERK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMERKPeersSector | |
---|---|---|---|---|
P/E Ratio | 12.7x | 14.0x | −0.7x | |
PEG Ratio | −0.56 | −0.19 | 0.00 | |
Price / Book | 2.2x | 1.8x | 2.6x | |
Price / LTM Sales | 1.7x | 1.5x | 3.1x | |
Upside (Analyst Target) | - | 32.1% | 49.0% | |
Fair Value Upside | Unlock | 19.2% | 7.4% | Unlock |